Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
NCT04119830Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in metastatic colorectal cancer (mCRC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Feb 2022; status: withdrawn.
02
Drugs
rintatolimod
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04119830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119830.